Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors

T cells engineered to express chimeric antigen receptors (CARs) specific for CD19 have yielded remarkable clinical outcomes in patients with refractory B-cell malignancies. The first CARs to be approved by the US Food and Drug Administration and the European Medicines Agency are CD19 CARs that compr...

Descripción completa

Detalles Bibliográficos
Autores principales: Feucht, J., Sadelain, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216534/
https://www.ncbi.nlm.nih.gov/pubmed/35757562
http://dx.doi.org/10.1016/j.iotech.2020.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216534/
https://www.ncbi.nlm.nih.gov/pubmed/35757562
http://dx.doi.org/10.1016/j.iotech.2020.09.001

Ejemplares similares